Matches in Wikidata for { <http://www.wikidata.org/entity/Q97684961> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q97684961 description "article scientifique publié en 2020" @default.
- Q97684961 description "articolo scientifico (pubblicato il 2020)" @default.
- Q97684961 description "artikull shkencor i botuar më 01 janar 2020" @default.
- Q97684961 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q97684961 description "im Januar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q97684961 description "scientific article published on 01 January 2020" @default.
- Q97684961 description "wetenschappelijk artikel" @default.
- Q97684961 description "наукова стаття, опублікована 1 січня 2020" @default.
- Q97684961 description "научна статия" @default.
- Q97684961 name "Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland" @default.
- Q97684961 name "Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland" @default.
- Q97684961 name "Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland" @default.
- Q97684961 type Item @default.
- Q97684961 label "Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland" @default.
- Q97684961 label "Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland" @default.
- Q97684961 label "Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland" @default.
- Q97684961 prefLabel "Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland" @default.
- Q97684961 prefLabel "Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland" @default.
- Q97684961 prefLabel "Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland" @default.
- Q97684961 P1433 Q97684961-6817C9C3-AE0B-462E-B63E-AC434C07B34F @default.
- Q97684961 P1476 Q97684961-D5591766-E5E1-49C0-9BF7-7B7B1E6F6BA2 @default.
- Q97684961 P2093 Q97684961-30650429-7BE4-4C54-ADA9-2C8D9CD6F762 @default.
- Q97684961 P2093 Q97684961-9AEF660A-6416-46AB-A7EF-6C3F99E28076 @default.
- Q97684961 P2093 Q97684961-AF38F754-EB49-4584-9BEA-0A0780C2C0F2 @default.
- Q97684961 P2093 Q97684961-D7A3E151-F317-4509-9F3E-634B9E517660 @default.
- Q97684961 P275 Q97684961-58c061b0-add5-40a6-afc1-ba6f1d6758f3 @default.
- Q97684961 P304 Q97684961-F9D55B31-08BE-4D41-A919-5E4828180E78 @default.
- Q97684961 P31 Q97684961-8292D386-C8A1-4028-8344-DBC3E8A66438 @default.
- Q97684961 P356 Q97684961-57FC8C0E-8089-4AF5-A4DC-E579030D410B @default.
- Q97684961 P433 Q97684961-2B43219A-0D7B-4098-A72D-8C99E01B529C @default.
- Q97684961 P478 Q97684961-7CCBF628-542C-4C41-9CBE-E13699164374 @default.
- Q97684961 P50 Q97684961-0A078A89-0A87-4F28-ACAC-088E9B2C6464 @default.
- Q97684961 P50 Q97684961-3E4FB969-68CA-4998-9E81-F1023E926FAA @default.
- Q97684961 P50 Q97684961-40950ADC-9DC9-453A-A41D-74D7A108C109 @default.
- Q97684961 P50 Q97684961-5A4635E9-E24D-498C-BBA7-E7DBDD714713 @default.
- Q97684961 P50 Q97684961-BDD7D22E-A4AE-4203-A765-F4FDF6ED6F9C @default.
- Q97684961 P50 Q97684961-F534C7F9-5853-4C06-B343-F4B45C7E213A @default.
- Q97684961 P50 Q97684961-F7FCE48E-77EE-426D-BE9D-AFB060B8B71F @default.
- Q97684961 P577 Q97684961-8BD0B255-B008-4E9F-87D9-2FE0ADE9BAAE @default.
- Q97684961 P6216 Q97684961-0977f55b-9f5e-4a62-baaf-5fb9614560e4 @default.
- Q97684961 P698 Q97684961-A0CBAC3D-4D88-4EB6-9822-26F12C6D5399 @default.
- Q97684961 P921 Q97684961-824C32B2-F3D2-4693-88F4-A05129FC8640 @default.
- Q97684961 P356 ARM.2020.0130 @default.
- Q97684961 P698 32706102 @default.
- Q97684961 P1433 Q96319659 @default.
- Q97684961 P1476 "Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland" @default.
- Q97684961 P2093 "Anna Wrona" @default.
- Q97684961 P2093 "Daria Świniuch" @default.
- Q97684961 P2093 "Dariusz M Kowalski" @default.
- Q97684961 P2093 "Grzegorz Czyżewicz" @default.
- Q97684961 P275 Q20007257 @default.
- Q97684961 P304 "189-196" @default.
- Q97684961 P31 Q13442814 @default.
- Q97684961 P356 "10.5603/ARM.2020.0130" @default.
- Q97684961 P433 "3" @default.
- Q97684961 P478 "88" @default.
- Q97684961 P50 Q114518695 @default.
- Q97684961 P50 Q116262397 @default.
- Q97684961 P50 Q53373129 @default.
- Q97684961 P50 Q58328150 @default.
- Q97684961 P50 Q59297718 @default.
- Q97684961 P50 Q85359336 @default.
- Q97684961 P50 Q92805623 @default.
- Q97684961 P577 "2020-01-01T00:00:00Z" @default.
- Q97684961 P6216 Q50423863 @default.
- Q97684961 P698 "32706102" @default.
- Q97684961 P921 Q36 @default.